Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 18/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | HTR7 | P34969 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5448221 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL5444520 | 0.95 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL5445154 | 0.90 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL5458928 | 0.89 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3CYP2D6CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL5446659 | 0.89 | SLC6A4 (0.79) | SLC6A4SLC6A2SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL5450614 | 0.86 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL5449348 | 0.86 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL5453605 | 0.82 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL5458859 | 0.82 | SLC6A2 (1.00) | SLC6A4SLC6A2SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL31061072 | 0.82 | SLC6A2 (1.00) | SLC6A4SLC6A2SLC6A3CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105870-A1 | Piperazine derivatives which exhibit activity as serotonin and noradrenaline re-uptake inhibitors | PFIZER INC. | 2007-05-10 | — | — | US | claimed |
| US-20070105870-A1 | Piperazine derivatives which exhibit activity as serotonin and noradrenaline re-uptake inhibitors | PFIZER INC. | 2007-05-10 | — | — | US | disclosed |
| US-20070105870-A1 | Piperazine derivatives which exhibit activity as serotonin and noradrenaline re-uptake inhibitors | PFIZER INC. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105870-A1 | Piperazine derivatives which exhibit activity as serotonin and noradrenaline re-uptake inhibitors | HTR3A, HTR3C, CYP4F3 | SLC6A4 26/4885SLC6A2 8/4885SLC6A3 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.